MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 577169 | Name: Mesalamine hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mesalamine hydrochloride is an anti-inflammatory agent, structurally related to the salicylates, which is active in Inflammatory Bowel Disease (IBD). It is considered to be the active moiety of sulphasalazine.

Chemical Structure

Mesalamine hydrochloride
CAS#6291-36-7

Theoretical Analysis

MedKoo Cat#: 577169

Name: Mesalamine hydrochloride

CAS#: 6291-36-7

Chemical Formula: C7H8ClNO3

Exact Mass: 189.0193

Molecular Weight: 189.59

Elemental Analysis: C, 44.35; H, 4.25; Cl, 18.70; N, 7.39; O, 25.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mesalamine hydrochloride; Mesalamine HCl
IUPAC/Chemical Name
Benzoic acid, 5-amino-2-hydroxy-, hydrochloride
InChi Key
KKRSNTURHSOKTM-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H7NO3.ClH/c8-4-1-2-6(9)5(3-4)7(10)11;/h1-3,9H,8H2,(H,10,11);1H
SMILES Code
Cl.Nc1ccc(O)c(c1)C(=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 189.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Rehman F, Rahim A, Airoldi C, Volpe PL. Preparation and characterization of glycidyl methacrylate organo bridges grafted mesoporous silica SBA-15 as ibuprofen and mesalamine carrier for controlled release. Mater Sci Eng C Mater Biol Appl. 2016 Feb;59:970-9. doi: 10.1016/j.msec.2015.11.005. Epub 2015 Nov 4. PubMed PMID: 26652455. 2: Andreas CJ, Chen YC, Markopoulos C, Reppas C, Dressman J. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release. Eur J Pharm Biopharm. 2015 Nov;97(Pt A):39-50. doi: 10.1016/j.ejpb.2015.09.002. Epub 2015 Sep 21. PubMed PMID: 26391972. 3: Torkashvand M, Gholivand MB, Taherkhani F. Fabrication of an electrochemical sensor based on computationally designed molecularly imprinted polymer for the determination of mesalamine in real samples. Mater Sci Eng C Mater Biol Appl. 2015 Oct;55:209-17. doi: 10.1016/j.msec.2015.05.031. Epub 2015 May 10. PubMed PMID: 26117757. 4: Boyle M, Ting A, Cury DB, Nanda K, Cheifetz AS, Moss A. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015 Dec;21(12):2873-8. doi: 10.1097/MIB.0000000000000562. PubMed PMID: 26313693. 5: OʼConnor A, Packey CD, Akbari M, Moss AC. Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov;21(11):2562-9. doi: 10.1097/MIB.0000000000000540. Review. PubMed PMID: 26296062. 6: Neufeld L, Bianco-Peled H. Designing a biocompatible hydrogel for the delivery of mesalamine. Int J Pharm. 2015 Aug 1;491(1-2):170-9. doi: 10.1016/j.ijpharm.2015.06.026. Epub 2015 Jun 23. PubMed PMID: 26116013. 7: Baker WL, Saulsberry WJ, Elliott K, Parker MW. Cardiac MRI-confirmed mesalamine-induced myocarditis. BMJ Case Rep. 2015 Sep 4;2015. pii: bcr2015210689. doi: 10.1136/bcr-2015-210689. PubMed PMID: 26341161. 8: Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Dig Dis Sci. 2016 Jan;61(1):221-9. doi: 10.1007/s10620-015-3866-7. Epub 2015 Nov 12. PubMed PMID: 26563167; PubMed Central PMCID: PMC4700064. 9: Tenjarla S. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels. Drugs R D. 2015 Jun;15(2):211-5. doi: 10.1007/s40268-015-0097-5. PubMed PMID: 26115756; PubMed Central PMCID: PMC4488180. 10: Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D, Kaimakliotis I, Eliakim R, Ng SC, Ben-Horin S. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1444-9.e1. doi: 10.1016/j.cgh.2015.02.019. Epub 2015 Feb 24. PubMed PMID: 25724700. 11: Zakko SF, Gordon GL, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP, Lichtenstein GR. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. Postgrad Med. 2016;128(3):273-81. doi: 10.1080/00325481.2016.1152876. Epub 2016 Mar 1. PubMed PMID: 26861051. 12: Nespoli L, Lo Bianco G, Uggeri F, Romano F, Nespoli A, Bernasconi DP, Gianotti L. Effect of oral mesalamine on inflammatory response in acute uncomplicated diverticulitis. World J Gastroenterol. 2015 Jul 21;21(27):8366-72. doi: 10.3748/wjg.v21.i27.8366. PubMed PMID: 26217088; PubMed Central PMCID: PMC4507106. 13: Abinusawa A, Tenjarla S. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels. Adv Ther. 2015 May;32(5):477-84. doi: 10.1007/s12325-015-0206-4. Epub 2015 May 8. PubMed PMID: 25951927; PubMed Central PMCID: PMC4449368. 14: Moss AC, Lillis Y, Edwards George JB, Choudhry NK, Berg AH, Cheifetz AS, Horowitz G, Leffler DA. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014 Dec;109(12):1850-5. doi: 10.1038/ajg.2014.158. Epub 2014 Jun 10. PubMed PMID: 24913040. 15: Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, Wolf D, Hardi R, Nessel L, Brensinger C, Gilroy E, Lewis JD; DEAR Investigators. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1887-93.e3. doi: 10.1016/j.cgh.2014.03.035. Epub 2014 Apr 30. PubMed PMID: 24793028; PubMed Central PMCID: PMC4214893.

View History

CCT367766

CCT367766